ClinicalTrials.gg
RecruitingNCT07479277E-SEALUpdated Mar 18, 2026

Progel Platinum for Air Leak Reduction After VATS Lobectomy for NSCLC

An interventional study of Progel Platinum and Mechanical Stapling in Non-Small Cell Lung Cancer, Postoperative Air Leak and NSCLC, sponsored by Fondazione del Piemonte per l'Oncologia. Recruiting at 6 sites in Italy. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-03-18.

Sponsored by Fondazione del Piemonte per l'Oncologia · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 716 studies in Carcinoma, Non-Small-Cell Lung with a site in Italy — 156 open to participants now, 286 under way, 104 of them phase 3. Carcinoma, Non-Small-Cell Lung · Italy.

Planned enrollment
405th of 640
160 · median 251
Started
2026
with 27 others
No phase
25 of 716
12 open now
Primary completion
2027-02
later than 120 of 285 live
Registered
697th of 716
by date

Among the 716 studies in Carcinoma, Non-Small-Cell Lung with a site in Italy, this one is the 405th largest by planned enrollment of the 640 interventional ones that give a count, is one of 28 that started in 2026, is one of 25 with no phase, reaches primary completion later than 120 of the 285 other live ones, and was the 697th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

156 of the 716 studies in Carcinoma, Non-Small-Cell Lung with a site in Italy are open now. Recruiting first, the newest first:

150 more — sign in →

All 156 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 716 studies in Carcinoma, Non-Small-Cell Lung with a site in Italy, or all of them as a file.
02

Study summary

This multicenter randomized trial evaluates whether routine use of Progel Platinum surgical sealant on stapled fissure lines during VATS upper or lower lobectomy for NSCLC reduces pleural drainage duration compared with standard stapling alone. Secondary objectives include postoperative length of stay, incidence and duration of postoperative air leaks, residual pleural space, safety outcomes, and hospitalization costs.

Read the detailed description

Lobectomy is the standard surgical treatment for many patients with early-stage NSCLC, but postoperative air leak remains a frequent complication associated with prolonged chest tube duration, longer hospitalization, and increased healthcare costs. Preliminary non-randomized evidence suggests that Progel Platinum may improve intraoperative sealing of fissure lines and reduce postoperative air leaks. E-SEAL is a prospective, randomized, controlled, multicenter study in 8 thoracic surgery centers. Eligible adult patients undergoing minimally invasive VATS upper or lower lobectomy for NSCLC are randomized 1:1 to stapling alone or stapling plus Progel Platinum. The primary endpoint is pleural drainage duration in hours. Secondary endpoints include postoperative length of stay, hospitalization costs, postoperative air leak incidence and volume, residual pleural space, complications, re-interventions, and follow-up outcomes up to 60 days after surgery/discharge.

03

Conditions studied

  • Non-Small Cell Lung Cancer
  • Postoperative Air Leak
  • NSCLC

Keywords

  • Non-Small Cell Lung Cancer
  • NSCLC
  • VATS Lobectomy
  • Postoperative air leak
  • Pleural drainage
  • Progel Platinum
  • Surgical sealant
  • Thoracic surgery
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • Written
  • Planned VATS upper or lower lobectomy for NSCLC
  • Minimally invasive thoracoscopic approach
  • Middle lobectomy excluded

Exclusion criteria

Exclusion Criteria:

  • Induction radiochemotherapy or chemo-immunotherapy
  • Severe : GOLD 3 or higher
  • Sleeve resection or extended resection involving other lobes/chest wall/pericardium, etc.
  • Albumin intolerance/allergy
  • Renal insufficiency
  • Redo surgery
  • Use of sealants/adhesives other than the study approach
  • Expected extensive pleural adhesions
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    Progel Group (PG)

    Fissure completion with mechanical staplers followed by application of Progel Platinum sealant along the fissure completion line.

    Device: Progel Platinum

  • Active comparator
    Standard Treatment Group (ST)

    Fissure completion with mechanical staplers alone, according to current standard practice.

    Procedure: Mechanical Stapling

Interventions

  • DeviceProgel Platinum

    Progel Platinum surgical sealant applied to the completed fissure line after stapled fissure completion during VATS upper or lower lobectomy

  • ProcedureMechanical Stapling

    Standard mechanical stapling used for fissure completion during VATS upper or lower lobectomy.

06

What researchers measure

Primary outcomes

  1. Duration of pleural drainage

    Time from surgery to chest tube removal, measured in hours.

    Time frame: From surgery to chest tube removal, assessed up to 30 days after surgery

Secondary outcomes

  1. Postoperative hospital length of stay

    Time from surgery to hospital discharge, measured in days.

    Time frame: From surgery to hospital discharge, assessed up to 30 days after surgery

  2. Incidence and volume of postoperative air leaks

    Proportion of patients with at least one documented postoperative air leak and mean daily and total postoperative air leak volume, as recorded by the digital drainage system.

    Time frame: Daily during postoperative hospitalization, from surgery until chest tube removal or hospital discharge, assessed up to 30 days after surgery

  3. Incidence of residual pleural space

    Proportion of patients with residual pleural space detected on chest imaging during postoperative hospitalization or at follow-up assessment.

    Time frame: During postoperative hospitalization and at follow-up visits at 1 month and 2 months after discharge

  4. Postoperative safety outcomes

    Incidence of postoperative adverse events and complications, including thoracentesis, new chest drainage, hospital readmission, and re-intervention.

    Time frame: During postoperative hospitalization and up to 30 days after surgery

  5. Duration of postoperative air leak

    Time from surgery to resolution of postoperative air leak, measured in hours.

    Time frame: From surgery to resolution of postoperative air leak during postoperative hospitalization, assessed up to 30 days after surgery

  6. Duration of surgical procedure

    Total duration of the surgical procedure, measured in minutes.

    Time frame: During the surgical procedure

  7. Mean daily and total postoperative air leak volume

    Mean daily postoperative air leak volume and cumulative total postoperative air leak volume, measured in liters using the digital drainage system.

    Time frame: Daily during postoperative hospitalization, from surgery until chest tube removal or hospital discharge, assessed up to 30 days after surgery

  8. Air leak indices corrected for length of dissected pulmonary parenchyma

    Quantitative postoperative air leak measures adjusted for the length of dissected pulmonary parenchyma to standardize comparisons between patients.

    Time frame: Daily during postoperative hospitalization, from surgery until chest tube removal or hospital discharge, assessed up to 30 days after surgery

07

Study locations

1 of 6 sites recruiting
  • Unità di Chirurgia Toracica Oncologica
    Candiolo, Torino 10060, Italy
    Recruiting
  • Ospedale centrale di Bolzano, Chirurgia Toracica e Vascolare
    Bolzano, Italy
    Not yet recruiting
    • Francesco Zaraca · Contact
  • Azienda Ospedaliero-Universitaria Careggi
    Florence, Italy
    Not yet recruiting
    • Alessandro Gonfiotti · Contact
  • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
    Milan, Italy
    Not yet recruiting
    • Mario Nosotti · Contact
  • Irccs Ismett
    Palermo, Italy
    Not yet recruiting
    • Alessandro Bertani · Contact
  • Azienda Ospedaliera-Universitaria Pisana
    Pisa, Italy
    Not yet recruiting
    • Marcello Carlo Ambrogi · Contact
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Feb 2027, 12 months after the start.

Of 345 non-industry interventional studies with no phase under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 97. This study's planned 12 months is below that.

Counting every sponsor, half of 361 studies reached it within 51 months; a quarter within 26 and three quarters within 97.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2026
First posted
Mar 18, 2026
StartActual
Feb 27, 2026
Primary completionEst.
Feb 27, 2027
CompletionEst.
Dec 31, 2027
Last update
Mar 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07479277
Lead sponsor
Fondazione del Piemonte per l'Oncologia
Responsible party
Sponsor
First posted
Mar 18, 2026
Start date
Feb 27, 2026
Primary completion
Feb 27, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Mar 18, 2026

Study contacts

Andrea Droghetti MD
Contact
andrea.droghetti@ircc.it
00390119933850
Annamaria Nuzzo PHD
Contact
annamaria.nuzzo@ircc.it
00390119933844

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion